Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monoethanolamine SCHEMBL27274629 | 0.87 | — | — | |
| Pyrrolidine SCHEMBL27815357 | 0.85 | ALDH1A1 (0.38) | ALDH1A1TSHRCXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL28046835 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TSHRCXCR4SMN1; SMN2 | |
| Piperazine SCHEMBL699478 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TSHRCXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL4128881 | 0.84 | ALDH1A1 (0.64) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL27814943 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TSHRCXCR4SMN1; SMN2 | |
| Pyrrolidine SCHEMBL2814299 | 0.81 | — | — | |
| Pyrrolidine SCHEMBL28301447 | 0.81 | — | — | |
| Monoethanolamine SCHEMBL28158530 | 0.80 | — | — | |
| Piperidine SCHEMBL28952742 | 0.79 | ALDH1A1 (0.56) | ALDH1A1TSHRCXCR4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290277-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RES CO LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-9095514-B2 | Pharmaceutical composition | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-08-04 | — | — | US | disclosed |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| CN-102292086-B | Pharmaceutical composition | SUN PHARMA ADVANCED RES CO LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8378099-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACUETICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| CN-102292086-A | Pharmaceutical composition | — | 2011-12-21 | — | — | CN | disclosed |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| EP-2379077-A2 | PHARMACEUTICAL COMPOSITION | Sun Pharma Advanced Research Company Limited (IN) | 2011-10-26 | — | — | EP | disclosed |
| US-6465433-B1 | SUCH AS N-(2-PYRIDINE)CARBONYL-L-PHENYLALANINE-L-LEUCINE BORONIC ACID; PROTEASOME INHIBITORS; REDUCING RATE OF MUSCLE PROTEIN DEGRADATION | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6297217-B1 | TREATMENT OF CANCER WITH PROTEASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5703104-A | Cyclic amides and derivatives thereof | DURHAM PHARMACEUTICALS LLC (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5559150-A | ANTICOAGULANT, ANTITUMOR, ANTIINFLAMMATORY | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| US-4108846-A | FOR PRODUCTION OF POLYPEPTIDES | HOFFMANN-LA ROCHE INC. | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | BCAT2, TTR, BCAT1 | ALDH1A1 2807/4885TSHR 1287/4885CXCR4 2211/4885 |
| US-20150290277-A1 | PHARMACEUTICAL COMPOSITION | BCAT2, TTR, BCAT1 | ALDH1A1 2807/4885TSHR 1287/4885CXCR4 2211/4885 |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | ALDH1A1 3283/4885TSHR 2235/4885CXCR4 343/4885 |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | ALDH1A1 3283/4885TSHR 2235/4885CXCR4 343/4885 |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | ALDH1A1 3283/4885TSHR 2235/4885CXCR4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.